Cargando…
CRLX101 (formerly IT-101)–A Novel Nanopharmaceutical of Camptothecin in Clinical Development
CRLX101 (formerly IT-101) is a first-in-class nanopharmaceutical, currently in Phase 2a development, which has been developed by covalently conjugating camptothecin (CPT) to a linear, cyclodextrin-polyethylene glycol (CD-PEG) co-polymer that self-assembles into nanoparticles. As a nanometer-scale dr...
Autores principales: | Young, Cissy, Schluep, Thomas, Hwang, Jungyeon, Eliasof, Scott |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers Ltd
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3182091/ https://www.ncbi.nlm.nih.gov/pubmed/22081768 http://dx.doi.org/10.2174/157340711795163866 |
Ejemplares similares
-
Preclinical effects of CRLX101, an investigational camptothecin-containing nanoparticle drug conjugate, on treating glioblastoma multiforme via apoptosis and antiangiogenesis
por: Lin, Chien-Ju, et al.
Publicado: (2016) -
A Systematic Review of Clinical Trials on the Efficacy and Safety of CRLX101 Cyclodextrin-Based Nanomedicine for Cancer Treatment
por: Serrano-Martínez, Ana, et al.
Publicado: (2023) -
Nanopharmaceutics
por: Ali, Javed
Publicado: (2011) -
Trends in Nanopharmaceutical Patents
por: Antunes, Adelaide, et al.
Publicado: (2013) -
Measurements of the beta-decay energy of $^{101}$Rb, $^{101,102}$Sr and $^{101,102}$Y
por: Balog, K, et al.
Publicado: (1990)